Chronic inflammatory demyelinating polyneuropathy: a treatment protocol proposal

References

• Austin JH. Recurrent polyneuropathies and their corticosteroid treatment; with five-year observations of a placebo-controlled case treated with corticotrophin, cortisone, and prednisone. Brain 81, 157–192 (1958).
   PubMed Web of Science ®Google Scholar
• Dyck PJ, Lais AC, Ohta M, Bastron JA, Okazaki H, Groover RV. Chronic inflammatory polyradiculoneuropathy. Mayo Clin. Proc. 50, 621–637 (1975).
   PubMed Web of Science ®Google Scholar
• Dyck PJ, O’Brien PC, Oviatt KF et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann. Neurol. 11, 136–141 (1982).
   PubMed Web of Science ®Google Scholar
• Gorson KC, Allam G, Ropper AH. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology 48, 321–328 (1997).
   PubMed Web of Science ®Google Scholar
• Rotta FT, Sussman AT, Bradley WG, Ram Ayyar D, Sharma KR, Shebert RT. The spectrum of chronic inflammatory demyelinating polyneuropathy. J. Neurol. Sci. 173, 129–139 (2000).
   PubMed Web of Science ®Google Scholar
• Saperstein DS, Katz JS, Amato AA, Barohn RJ. Clinical spectrum of chronic acquired demyelinating polyneuropathy. Muscle Nerve 24, 311–324 (2001).
   PubMed Web of Science ®Google Scholar
• Busby M, Donaghy M. Chronic dysimmune neuropathy: a subclassification based upon the clinical features of 102 patients. J. Neurol. 250, 714–724 (2003).
   PubMed Web of Science ®Google Scholar
• Köller H, Kieseier BC, Jander S, Hartung HP. Chronic inflammatory demyelinating polyneuropathy. N. Engl. J. Med. 352, 1343–1356 (2005).
   PubMed Web of Science ®Google Scholar
• Magda P, Latov N, Brannagan TH 3rd, Weimer LH, Chin RL, Sander HW. Comparison of electrodiagnostic abnormalities and criteria in a cohort of patients with chronic inflammatory demyelinating polyneuropathy. Arch. Neurol. 60, 1755–1759 (2003).
   PubMed Web of Science ®Google Scholar
• Sander HW, Latov N. Research criteria for defining patients with CIDP. Neurology 60(Suppl.), S8–S15 (2003).
   PubMed Web of Science ®Google Scholar
• Van den Bergh PY, Piéret F. Electrodiagnostic criteria for acute and chronic inflammatory demylinating polyradioculoneuropathy. Muscle Nerve 29, 565–574 (2004) .
   PubMed Web of Science ®Google Scholar
• Dyck PJ, Daube J, O’Brien P et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N. Engl. J. Med. 314, 461–465 (1986).
   PubMed Web of Science ®Google Scholar
• Hahn AF, Bolton CF, Pillay N et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy: a double-blind, sham-controlled, cross-over study. Brain 119, 1055–1066 (1996).
   PubMed Web of Science ®Google Scholar
• van Doorn PA, Brand A, Strengers PFW, Meulstee J, Vermeulen M. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology 40, 209–212 (1990).
   PubMed Web of Science ®Google Scholar
• Vermeulen M, van Doorn PA, Brand A, Strengers PFW, Jennekens FGI, Busch HFM. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled study. J. Neurol. Neurosurg. Psychiatry 56, 36–39 (1993).
   PubMed Web of Science ®Google Scholar
• Hahn AF, Bolton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, cross-over study. Brain 119, 1067–1077 (1996).
   PubMed Web of Science ®Google Scholar
• Thompson N, Choudhary P, Hughes RAC, Quinlivan RM. A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. J. Neurol. 243, 280–285 (1996).
   PubMed Web of Science ®Google Scholar
• Mendell JR, Barohn RJ, Freimer ML et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 56, 445–449 (2001).
   PubMed Web of Science ®Google Scholar
• Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J. Peripher. Nerv. Syst. 10, 220–228 (2005).
   PubMed Web of Science ®Google Scholar
• Odaka M, Tatsumoto M, Susuki K, Hirata K, Yuki N. Intractable chronic inflammatory demyelinating polyneuropathy treated successfully with ciclosporin. J. Neurol. Neurosurg. Psychiatry 76, 1115–1120 (2005).
   PubMed Web of Science ®Google Scholar
• Verma A, Tandan R, Adesina AM, Pendlebury WW, Fries TJ, Bradley WG. Focal neuropathy preceding chronic inflammatory demyelinating polyradiculoneuropathy by several years. Acta. Neurol. Scand. 81, 516–521 (1990).
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Engel WK. Chronic relapsing (dysimmune) polyneuropathy: pathogenesis and treatment. Ann. Neurol. 9(Suppl.), 134–145 (1981).
   PubMed Web of Science ®Google Scholar
• McCombe PA, Pollard JD, McLeod JG. Chronic inflammatory demyelinating polyradiculoneuropathy: a clinical and electrophysiological study of 92 cases. Brain 110, 1617–1630 (1987).
   PubMed Web of Science ®Google Scholar
• Barohn RJ, Kissel JT, Warmolts JR, Mendell JR. Chronic inflammatory demyelinating polyradiculoneuropathy: clinical characteristics, course, and recommendations for diagnostic criteria. Arch. Neurol. 46, 878–884 (1989).
   PubMed Web of Science ®Google Scholar
• Donaghy M, Earl CJ. Ocular palsy preceding chronic relapsing polyneuropathy by several weeks. Ann. Neurol. 17, 49–50 (1985).
   PubMed Web of Science ®Google Scholar
• Prineas JW, McLeod JG. Chronic relapsing polyneuritis. J. Neurol. Sci. 27, 427–458 (1976).
   PubMed Web of Science ®Google Scholar
• Lunn MPT, Manji H, Choudhary PP, Hughes RAC, Thomas PK. Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England. J. Neurol. Neurosurg. Psychiatry 66, 677–680 (1999).
   Google Scholar
• Kuwabara S, Nakajima M, Matsuda S, Hattori T. Magnetic resonance imaging at the demyelinative foci in chronic inflammatory demyelinating polyneuropathy. Neurology 48, 874–877 (1997).
   PubMed Web of Science ®Google Scholar
• Duggins AJ, McLeod JG, Pollard JD et al. Spinal root and plexus hypertrophy in chronic inflammatory demyelinating polyneuropathy. Brain 122, 1383–1390 (1999).
   PubMed Web of Science ®Google Scholar
• Bouchard C, Lacroix C, Planté V et al. Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy. Neurology 52, 498–503 (1999).
   PubMed Web of Science ®Google Scholar
• Yan WX, Archelos JJ, Hartung HP, Pollard JD. P0 protein is a target antigen in chronic inflammatory demyelinating polyradiculoneuropathy. Ann. Neurol. 50, 286–292 (2001).
   PubMed Web of Science ®Google Scholar
• Allen D, Giannopoulos K, Gray I et al. Antibodies to peripheral nerve myelin proteins in chronic inflammatory demyelinating polyradiculoneuropathy. J. Peripher. Nerv. Syst. 10, 174–180 (2005).
   PubMed Web of Science ®Google Scholar
• Schmidt B, Toyka KV, Kiefer R, Full J, Hartung HP, Pollard J. Inflammatory infiltrates in sural nerve biopsies in Guillain–Barré syndrome and chronic inflammatory demyelinating neuropathy. Muscle Nerve 19, 474–487 (1996).
   PubMed Web of Science ®Google Scholar
• Bosboom WMJ, van den Berg LH, de Boer L et al. The diagnostic value of sural nerve T-cells in chronic inflammatory demyelinating polyneuropathy. Neurology 53, 837–845 (1999).
   PubMed Web of Science ®Google Scholar
• Report from an ad hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Neurology 41, 617–618 (1991).
   PubMed Web of Science ®Google Scholar
• Oh SJ, Claussen GC, Kim DS. Motor and sensory demyelinating mononeuropathy multiplex (multifocal motor and sensory demyelinating neuropathy): a separate entity or a variant of chronic inflammatory demyelinating polyneuropathy? J. Peripher. Nerv. Syst. 2, 362–369 (1997).
   PubMedGoogle Scholar
• Saperstein DS, Amato AA, Wolfe GI et al. Multifocal acquired demyelinating sensory and motor neuropathy: the Lewis–Sumner syndrome. Muscle Nerve 22, 560–566 (1999).
   PubMed Web of Science ®Google Scholar
• Katz JS, Saperstein DS, Gronseth G, Amato AA, Barohn RJ. Distal acquired demyelinating symmetric neuropathy. Neurology 54, 615–620 (2000).
   PubMed Web of Science ®Google Scholar
• van den Berg-Vos RM, van den Berg LH, Franssen H et al. Multifocal inflammatory demyelinating neuropathy: a distinct clinical entity? Neurology 54, 26–32 (2000).
   PubMed Web of Science ®Google Scholar
• Mygland Å, Monstad P. Chronic acquired demyelinating symmetric polyneuropathy classified by pattern of weakness. Arch. Neurol. 60, 260–264 (2003).
   PubMedGoogle Scholar
• Oh SJ, Kurokawa K, de Almeida DF, Ryan HF Jr, Claussen GC. Subacute inflammatory demyelinating polyneuropathy. Neurology 61, 1507–1512 (2003).
   PubMed Web of Science ®Google Scholar
• Sinnreich M, Klein CJ, Daube JR, Engelstad J, Spinner RJ, Dyck PJB. Chronic immune sensory polyradiculopathy: a possibly treatable sensory ataxia. Neurology 63, 1662–1669 (2004).
   PubMed Web of Science ®Google Scholar
• Katz JS, Saperstein DS. Asymmetric acquired demyelinating polyneuropathies: MMN and MADSAM. Curr. Treat. Options Neurol. 3, 119–125 (2001).
   PubMedGoogle Scholar
• Tagawa Y, Yuki N, Hirata K. Anti-SGPG antibody in CIDP: nosological position of IgM antiMAG/SGPG antibody-associated neuropathy. Muscle Nerve 23, 895–899 (2000).
   PubMed Web of Science ®Google Scholar
• Olney RK. Guidelines in electrodiagnostic medicine: consensus criteria for the diagnosis of partial conduction block. Muscle Nerve 22(Suppl.), S225–S229 (1999).
   Google Scholar
• Hughes R, Bensa S, Willison H et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann. Neurol. 50, 195–201 (2001).
   PubMed Web of Science ®Google Scholar
• Odaka M, Yuki N, Hirata K. Patients with chronic inflammatory demyelinating polyneuropathy initially diagnosed as Guillain–Barré syndrome. J. Neurol. 250, 913–916 (2003).
   PubMed Web of Science ®Google Scholar
• Mehndiratta MM, Hughes RAC. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst. Rev. 1, CD002062 (2002).
   Google Scholar
• Bromberg MB, Carter O. Corticosteroid use in the treatment of neuromuscular disorders: empirical and evidence-based data. Muscle Nerve 30, 20–37 (2004).
   PubMed Web of Science ®Google Scholar
• van Schaik IN, Winer JB, de Haan R, Vermeulen M. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst. Rev. 2, CD001797 (2002).
   Google Scholar
• Dyck PJ, Litchy WJ, Kratz KM et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann. Neurol. 36, 838–845 (1994).
   PubMed Web of Science ®Google Scholar
• Saxon A, Stevens RH, Ramer SJ, Clements PJ, Yu DTY. Glucocorticoids administered in vivo inhibit human suppressor T-lymphocyte function and diminish B-lymphocyte responsiveness in in vitro immunoglobulin synthesis. J. Clin. Invest. 61, 922–930 (1978).
   PubMed Web of Science ®Google Scholar
• van Schaik IN, Winer JB, de Haan R, Vermeulen M. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review. Lancet Neurol. 1, 491–498 (2002).
   PubMed Web of Science ®Google Scholar
• van Doorn PA. Treatment of Guillain–Barré syndrome and CIDP. J. Peripher. Nerv. Syst. 10, 113–127 (2005).
   PubMed Web of Science ®Google Scholar
• Wertman E, Argov Z, Abrmasky O. Chronic inflammatory demyelinating polyradiculoneuropathy: features and prognostic factors with corticosteroid therapy. Eur. Neurol. 28, 199–204 (1988).
   PubMed Web of Science ®Google Scholar
• Hughes RAC, Swan AV, van Doorn PA. Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst. Rev. 4, CD003280 (2004).
   Google Scholar
• Hefter H, Sprenger KBG, Arendt G, Hafner D. Treatment of chronic relapsing inflammatory demyelinating polyneuropathy by cyclosporin A and plasma exchange: a case report. J. Neurol. 237, 320–333 (1990).
   PubMed Web of Science ®Google Scholar
• Hodgkinson SJ, Pollard JD, McLeod JG. Cyclosporin A in the treatment of chronic demyelinating polyradiculoneuropathy. J. Neurol. Neurosurg. Psychiatry 53, 327–330 (1990).
   PubMed Web of Science ®Google Scholar
• Mahattanakul W, Crawford TO, Griffin JW, Goldstein JM, Cornblath DR. Treatment of chronic inflammatory demyelinating polyneuropathy with cyclosporin-A. J. Neurol. Neurosurg. Psychiatry 60, 185–187 (1996).
   PubMed Web of Science ®Google Scholar
• Barnett MH, Pollard JD, Davies L, McLeod JG. Cyclosporin A in resistant chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 21, 454–460 (1998).
   PubMed Web of Science ®Google Scholar
• Matsuda M, Hoshi K, Gono T, Morita H, Ikeda S. Cyclosporin A in treatment of refractory patients with chronic inflammatory demyelinating polyradiculoneuropathy. J. Neurol. Sci. 224, 29–35 (2004).
   PubMed Web of Science ®Google Scholar
• Kahan BD. Cyclosporin. N. Engl. J. Med. 321, 1725–1736 (1989).
   PubMed Web of Science ®Google Scholar
• Kurki PT. Safety aspects of the long-term cyclosporin A therapy. Scand. J. Rheumatol. 95(Suppl.), 35–38 (1992).
   Google Scholar
• Correia O, Polonia J, Nunes JP, Resende C, Delgado L. Severe acute form of adult dermatomyositis treated with cyclosporin. Int. J. Dermatol. 31, 517–519 (1992).
   PubMed Web of Science ®Google Scholar
• Amato AA, Griggs RC. Treatment of idiopathic inflammatory myopathies. Curr. Opin. Neurol. 16, 569–575 (2003).
   PubMed Web of Science ®Google Scholar
• Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol. Today 13, 136–142 (1992).
   PubMedGoogle Scholar
• Ho S, Clipstone N, Timmermann L et al. The mechanism of action of cyclosporin A and FK506. Clin. Immunol. Immunopathol. 80(Suppl.), S40–S45 (1996).
   Google Scholar
• Kieseier BC, Dalakas MC, Hartung HP. Immune mechanisms in chronic inflammatory demyelinating neuropathy. Neurology 59(Suppl.), S7–S12 (2002).
   PubMedGoogle Scholar
• Good JL, Chehrenama M, Mayer RF, Koski CL. Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy. Neurology 51, 1735–1738 (1998).
   PubMed Web of Science ®Google Scholar
• Gladstone DE, Prestrud AA, Brannagan TH 3rd. High-dose cyclophosphamide results in long-term disease remission with restoration of a normal quality of life in patients with severe refractory chronic inflammatory demyelinating polyneuropathy. J. Peripher. Nerv. Syst. 10, 11–16 (2005).
   Google Scholar
• Ahlmén J, Andersen O, Hallgren G, Peilot B. Positive effects of tacrolimus in a case of CIDP. Transplant. Proc. 30, 4194 (1998).
   PubMed Web of Science ®Google Scholar
• Gorson KC, Ropper AH, Clark BD, Dew RB 3rd, Simovic D, Allam G. Treatment of chronic inflammatory demyelinating polyneuropathy with interferon-α 2a. Neurology 50, 84–87 (1998).
   PubMed Web of Science ®Google Scholar
• Hadden RDM, Sharrack B, Bensa S, Soudain SE, Hughes RAC. Randomized trial of interferon β-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 53, 57–61 (1999).
   PubMed Web of Science ®Google Scholar
• Vallat JM, Hahn AF, Léger JM et al. Interferon β-1a as an investigational treatment for CIDP. Neurology 60(Suppl.), S23–S28 (2003).
   PubMedGoogle Scholar
• Mowzoon N, Sussman A, Bradley WG. Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. J. Neurol. Sci. 185, 119–122 (2001).
   PubMed Web of Science ®Google Scholar
• Benedetti L, Grandis M, Nobbio L et al. Mycophenolate mofetil in dysimmune neuropathies: a preliminary study. Muscle Nerve 29, 748–749 (2004).
   PubMed Web of Science ®Google Scholar
• Gorson KC, Amato AA, Ropper AH. Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy. Neurology 63, 15–17 (2004).
   Web of Science ®Google Scholar
• Chin RL, Sherman WH, Sander HW, Hays AP, Latov N. Etanercept (Enbrel®) therapy for chronic inflammatory demyelinating polyneuropathy. J. Neurol. Sci. 210, 19–21 (2003).
   PubMed Web of Science ®Google Scholar
• Vermeulen M, van Oers MH. Successful autologous stem cell transplantation in a patient with chronic inflammatory demyelinating polyneuropathy. J. Neurol. Neurosurg. Psychiatry 72, 127–128 (2002).
   PubMed Web of Science ®Google Scholar
• Pestronk A, Florence J, Miller T, Choksi R, Al-Lozi MT, Levine TD. Treatment of IgM antibody associated polyneuropathies using rituximab. J. Neurol. Neurosurg. Psychiatry 74, 485–489 (2003).
   PubMed Web of Science ®Google Scholar
• Renaud S, Gregor M, Fuhr P et al. Rituximab in the treatment of polyneuropathy associated with antiMAG antibodies. Muscle Nerve 27, 611–615 (2003).
   PubMed Web of Science ®Google Scholar